%202.png)
STEP 1
Complete a short questionnaire
Share your health history, goals, and preferences online or in person.
Start knownwell’s questionnaire.
Start knownwell’s questionnaire.
Comprehensive, empathetic healthcare — with GLP-1 support*
%202.svg)
GET A FOUNDAYO™ PRESCRIPTION FOR WEIGHT MANAGEMENT
Meet Foundayo™
Get a Foundayo™ prescription starting at $149
12.4% average reduction in weight
Oral medication prescribed as part of a personalized care plan
.webp)
.svg)
Get bias-free weight management with knownwell
World-class experts in weight management
Board-certified in Obesity Medicine (ABOM) clinicians who are up-to-date on the latest research in weight care.
.svg)
In-network with insurance
We work with major insurance plans to help make your care and prescription as affordable as possible.
Prior authorization support
Our dedicated team helps get your Wegovy® prescription covered — so you're not navigating coverage alone
In-person & virtual availability
Available via telehealth nationwide, with in-person clinics in select cities
What you need to know about Foundayo™
WHAT’S ON THIS PAGE
WHAT’S ON THIS PAGE
About Foundayo™
What to Expect
A Closer Look at Foundayo™
A Closer Look at Foundayo™
Frequently asked questions about Foundayo™Ready to see if Foundayo™ is right for you?Nutrition tips while taking Foundayo™The Real Science Behind Foundayo™The History of GLP-1sImportant safety informationABOUT FOUNDAYO™
What is Foundayo™?
%202%20(1).svg){kind=icon}
Foundayo™ is a prescription medication FDA-approved for chronic weight management in adults with obesity, or adults with overweight and at least one weight-related health condition. Researchers are also studying its use in treating a range of other conditions, including type 2 diabetes.
Foundayo™ belongs to a class of medications called GLP-1 receptor agonists, which work with the body's natural hunger and blood sugar signals to help regulate appetite and support metabolic health.
Unlike injectable GLP-1 medications or peptide-based oral options, orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist.
This means it’s a once-daily pill that can be taken at any time of day, without restrictions on food or water intake. It’s a more convenient option for people who’d rather not use injections or follow guidelines about timing their dose on an empty stomach.
Because of how it works in the body, orforglipron can support meaningful, sustained weight reduction, making it a valuable part of a comprehensive care plan for people managing their weight and related health conditions.Your care team will help determine if it's the right fit, based on your health history, goals, and treatment needs.
.webp)
How Foundayo™ works
What it does in the body
Foundayo® is a GLP-1 receptor agonist. It mimics GLP-1, a naturally occurring hormone released after you eat that helps regulate blood sugar, appetite, and digestion.
By activating GLP-1 receptors, Foundayo® works to increase insulin secretion when blood sugar is elevated, reduce glucagon (a hormone that raises blood sugar), slow the rate at which food leaves the stomach, and reduce hunger signals in the brain.
Self-pay option available
By working with these natural hormone signals, the medication helps reduce appetite and increase feelings of fullness, making it easier to eat in alignment with your health goals.
Over time, people using Foundayo® as part of a broader care plan often see meaningful, sustained reductions in body weight.
Many people may notice
- Reduced hunger and fewer cravings between meals
- Feeling satisfied sooner and for longer after eating
- Gradual, sustained weight reduction over time
COST & COVERAGE
Is Foundayo™ covered by insurance?
Foundayo™ can be covered by insurance, but it depends on your plan.
Many commercial plans are expected to include Foundayo™ on their formularies for weight management. Still, coverage will vary by plan, employer, and pharmacy benefit structure.
Also, prior authorization may be required. Plans may ask for documentation of a qualifying diagnosis, BMI, and any previous medications tried.
knownwell helps patients navigate this process. Our dedicated authorization team can assist with prior benefit verification and next steps, so you understand your coverage options before moving forward.
.svg)
.svg%201%20%5BVectorized%5D.svg)
How much does Foundayo™ cost?
Insurance accepted
With insurance, Foundayo® can cost as little as $0.80 per day ($25 per month) for eligible commercially insured patients using the Foundayo® savings card. Actual costs vary based on your plan, benefits, pharmacy, and prescribed dose.
knownwell's care team helps review your coverage and navigate any required approvals, so you understand your options before starting treatment.
Self-pay option available
If you're paying without insurance, Lilly has announced that self-paying patients will be able to access Foundayo® through LillyDirect's self-pay pharmacy channel, with the lowest dose starting at $149 per month and additional doses costing up to $399 per month.
The company also says that eligible patients enrolled in Medicare Part D may be able to access Foundayo® for $50 per month, beginning as soon as July 1, 2026.
Your knownwell care team will review costs with you as part of your plan.
.png)
.png)
.svg)
.png){kind=icon}
Starting at $149 per month
for the 0.8 mg dose via Lilly Direct. Foundayo™ is prescribed as part of a personalized medication plan with ongoing support from your knownwell care team. knownwell clinicians will only prescribe medicine that is clinically appropriate.
.svg)
WHAT TO EXPECT
What results can you expect?
Clinical studies show that Foundayo™ can support meaningful weight reduction over time for many people, when used consistently as part of a broader weight management plan.
What the trials show
The ATTAIN-1 72-week clinical trial enrolled over 3,100 adults with obesity (without diabetes). Participants lost an average of 7.5% of their body weight on the 5.5 mg tablet, 8.4% on the 9 mg tablet, and 11.2% on the 17.2 mg tablet, compared to 2.1% for those who took a placebo. More than half of the participants taking the highest dose achieved at least 10% weight reduction, and more than a third achieved at least 15%.
.svg)
Metabolic effects
Orforglipron has also been shown to deliver significant improvements in blood sugar control and weight reduction for adults with type 2 diabetes. In the ACHIEVE-3 head-to-head trial, orforglipron 17.2 mg produced 73.6% greater relative weight loss compared to oral semaglutide 14 mg, alongside meaningfully greater reductions in HbA1c.
.svg)
Cardiometabolic health
Body composition
Waist circumference decreased by up to ~10 cm (~4 inches), reflecting meaningful reductions in visceral fat.
.svg)
After 1 year...
83%
of knownwell patients lost ≥10% of body weight and 74% of patients lost ≥ 20% of their body weight
.png)
97%
of knownwell patients have sustained weight loss
15%
average reduction in body mass
How to get Foundayo™ with knownwell
Complete a short questionnaire
Meet with a knownwell clinician
Receive a prescription, if appropriate
Get your medication
STEP 2
Meet with a healthcare clinician
A knownwell care team member reviews your information and discusses treatment options with you.
STEP 3
Receive a prescription, if appropriate
If Foundayo™ is a good fit, your care team will prescribe the medication and outline next steps.
STEP 4
Get your medication
Foundayo™ is provided through knownwell, with guidance on how and when to start, plus ongoing support along the way.
A CLOSER LOOK AT FOUNDAYO™
Frequently asked questions
What side effects should I know about?
Who should not take Foundayo™?
How is Foundayo™ taken?
How is Foundayo™ stored?
What should I know about Foundayo™ dosing?
Nutrition tips while taking Foundayo™
Studies show that Foundayo™ can support meaningful weight reduction over time for many people, when used consistently as part of a broader weight management plan.
%20(1).png)
Choose balanced, nutrient-rich meals
Focus on whole foods like vegetables, lean proteins, and whole grains to support overall health and make meals feel satisfying.
Hydrate throughout the day.
Drinking water regularly can help with appetite cues and support weight management.
Pay attention to how you feel after meals.
Because Foundayo™ can change hunger signals and sometimes cause digestive symptoms, smaller, slower meals can be easier to tolerate early in treatment.
Plan meals around your routine.
Eating when you’re truly hungry and spacing meals evenly can help support appetite regulation as your body adjusts.
These general patterns fit with how Foundayo™ works in the body and can help support your treatment goals alongside your care team's guidance.
.png)
.png)
Explore medication options
Wegovy® can be used as a daily oral medication or weekly injection. It has strong clinical evidence supporting weight loss outcomes of 15–20%.
Qsymia® or Contrave® Daily or twice-daily pill alternatives for those who prefer to avoid injections, with typical outcomes ranging from 5–10% weight loss.
Zepbound® A dual GLP-1/GIP receptor agonist that targets two appetite-related pathways, with clinical outcomes of 15–23% weight loss.
Ready to see if Foundayo™ is right for you?
Meet with a knownwell provider to review your options, discuss whether Foundayo™ fits your needs, and get guidance on next steps.
knownwell knows that long-term weight management support is critical. That's why our patients meet with the same clinician throughout their entire time at knownwell.
The science of Foundayo™
A closer look at dual incretin biology, peptide engineering, and metabolic effects
Foundayo™ is the first oral, non-peptide GLP-1 receptor agonist designed for weight management
Foundayo™ is unlike any GLP-1 medication that came before it. It’s a small-molecule, non-peptide GLP-1 receptor agonist, meaning it activates the same GLP-1 receptor as injectable medications like semaglutide and tirzepatide, but through an entirely different molecular design.
Most GLP-1 medications are peptides. These are short proteins that must be injected because they’d be broken down by stomach acids and digestive enzymes if taken orally.The one peptide-based oral GLP-1 available (oral semaglutide) requires specific dosing conditions: it must be taken on an empty stomach with a small amount of water, followed by a 30-minute fast.
Foundayo™ solves this problem through its non-peptide structure. Because it’s a small molecule rather than a protein, it’s naturally resistant to degradation in the digestive system. This means it can be taken as a once-daily pill at any time of day, with or without food, and without restrictions on water intake.
Foundayo™'s pharmacokinetic profile supports once-daily dosing, providing consistent levels of the medication throughout the day.
This convenience is what distinguishes Foundayo™ from both injectable GLP-1 medications and existing oral peptide-based options. It may expand access to GLP-1 therapy for people who prefer not to use injections or find existing oral dosing requirements difficult to follow.
Central nervous system effects: Appetite regulation at the source
GLP-1 receptors are expressed in areas of the brain involved in appetite and energy balance, including the hypothalamus and the brainstem.When orforglipron, the active ingredient in Foundayo®, activates these receptors in the brain, it:
- Increases satiety signaling
- Reduces food intake
- May reduce food cravings
- Decreases overall caloric intake over time
This isn’t appetite suppression in the stimulant sense. It's a modulation of the body's own hunger signals, working with the brain's natural regulation systems to help eating feel more naturally controlled.
Metabolic and cardiometabolic effects
Foundayo™’s effects extend beyond weight reduction. In clinical trials, treatment with the active ingredient, orforglipron, was associated with improvements in cardiometabolic markers, including:
- Reductions in waist circumference
- Improvements in systolic blood pressure
- Reductions in triglyceride levels
- Improvements in non-HDL cholesterol levels
In the ACHIEVE-3 trial, which included adults with type 2 diabetes, orforglipron also showed clinically meaningful improvements across key cardiovascular risk factors, including non-HDL cholesterol, HDL cholesterol, VLDL cholesterol, total cholesterol, systolic blood pressure, and triglycerides.Among participants in ATTAIN-1 who had prediabetes at the start of the study, up to 83.7% of those taking orforglipron achieved near-normal blood sugar levels, compared with 44.6% of those taking a placebo.
The history of GLP-1 medications
1980s–1990s:
Discovery of GLP-1
Discovery of GLP-1
2000s:
The Gila Monster Connection
The Gila Monster Connection
2010s:
Longer-acting GLP-1 Medications
Longer-acting GLP-1 Medications
2021–Present:
GLP-1s for Weight Management
GLP-1s for Weight Management
1980s - 1990s
Discovery of GLP-1
Scientists first identified glucagon-like peptide-1 (GLP-1) as a naturally occurring hormone released from the gut after eating.
Researchers discovered that GLP-1 helps:
Researchers discovered that GLP-1 helps:
- Stimulate insulin release
- Reduce glucagon (a hormone that raises blood sugar)
- Slow stomach emptying
- Signal fullness to the brain
This made GLP-1 a promising target for treating type 2 diabetes
2000s
The Gila Monster Connection
While researching ways to extend GLP-1's lifespan in the body, scientists made a surprising find: Gila monster saliva contains exendin-4, a compound similar to human GLP-1 but far more resistant to breakdown.
In 2005, this led to the first FDA-approved GLP-1 receptor agonist, Exenatide (Byetta®) — lasting long enough, unlike natural GLP-1, to be used therapeutically.
In 2005, this led to the first FDA-approved GLP-1 receptor agonist, Exenatide (Byetta®) — lasting long enough, unlike natural GLP-1, to be used therapeutically.
2010s
Longer-acting GLP-1 Medications
As research advanced, medication modifications became more refined — leading to longer-acting medications like liraglutide (Saxenda®) and semaglutide (Ozempic®, Wegovy®).
Semaglutide is ~94% similar to natural GLP-1 but engineered to resist breakdown, enabling once-weekly dosing with significantly improved outcomes for both blood sugar control and weight management.
Semaglutide is ~94% similar to natural GLP-1 but engineered to resist breakdown, enabling once-weekly dosing with significantly improved outcomes for both blood sugar control and weight management.
2021 - Present
The Small-molecule Breakthrough
While peptide-based GLP-1 medications were advancing, a parallel line of research pursued a fundamentally different approach. Researchers designed a small-molecule compound that could activate the GLP-1 receptor without the limitations of a peptide medication.
Small-molecule oral GLP-1 therapies like Foundayo® represent a new chapter in metabolic medicine, offering the biological benefits of GLP-1 receptor activation in a convenient, once-daily pill that can be taken without restrictions.
Small-molecule oral GLP-1 therapies like Foundayo® represent a new chapter in metabolic medicine, offering the biological benefits of GLP-1 receptor activation in a convenient, once-daily pill that can be taken without restrictions.
Important safety information
Foundayo® is an FDA-approved prescription medication for chronic weight management in adults with obesity, or in adults with overweight who have at least one weight-related health condition, used alongside a healthy diet and increased physical activity.
Like all medications, it isn't right for everyone.
Like all medications, it isn't right for everyone.
Who should not take Foundayo™
- People with a personal or family history of medullary thyroid cancer (MTC)
- People with a rare endocrine condition called multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Anyone who’s had a serious allergic reaction to orforglipron or any other ingredient in Foundayo®
Talk with your care team if you have a history of:
- Any pancreas or kidney conditions
- Severe problems with your liver, stomach, or digestion
- An eye condition called diabetic retinopathy
- Vision problems related to diabetes
It’s important to let your care team know if you’re pregnant, or planning to become pregnant or breastfeed. Also, if you take oral birth control pills, these may not work as well while you’re taking Foundayo®. Your care team may recommend another form of birth control for 30 days after starting Foundayo® and for 30 days after each dose increase.
Finally, reach out to your care team if you have any procedures scheduled that require sedation or anesthesia.
What to watch for
Some side effects require prompt medical attention, including:
- Severe or ongoing abdominal pain, which may extend to your back
- Signs of a serious allergic reaction, such as swelling or trouble breathing
- Symptoms of very low blood sugar, such as dizziness and a fast heartbeat, especially if you take diabetes medications
- Signs of gallbladder problems, such as a fever or yellowing of your eyes
- Any changes in vision
- Possible symptoms of thyroid cancer, such as swelling or a lump in your neck, or unexplained hoarseness, trouble swallowing, or shortness of breath
Your knownwell care team will review your health history, medications, and safety considerations before prescribing Foundayo®, and will continue to support you throughout the treatment.
.webp)
.png)
DISCLAIMERS & SOURCES
Disclaimers
In the ATTAIN-1 trial, individuals taking the highest dose of Foundayo and who stayed on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo. Participants taking Foundayo, regardless of trial completion, lost an average of 25 pounds (11.1%), compared to 5.3 pounds (2.1%) with placebo.
Sources
1.
Collins, L., Costello, R. A. (2024, February 29). Glucagon-like peptide-1 receptor agonists. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK551568/
2.
Davy, B. M., Davy, K. P., Savla, J. T., et al. (2025). Water intake, hydration, and weight management: the glass is half-full! Physiology & Behavior, 297, 114953. doi:10.1016/j.physbeh.2025.114953. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40374025/
3.
Eli Lilly and Company. (2026, April 1). FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions [Press release]. Retrieved from https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
4.
Eli Lilly and Company. (2025, September 16). Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in the New England Journal of Medicine [Press release]. Retrieved from https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight
5.
Eli Lilly and Company. (2025, June 21). Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in the New England Journal of Medicine [Press release]. Retrieved from https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-showed-compelling-efficacy-and
See all
6.
Eli Lilly and Company. (2025, December 18). Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial [Press release]. Retrieved from https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after
7.
Eli Lilly and Company. (2025). What to know about orforglipron oral GLP-1. Retrieved from https://www.lilly.com/news/stories/what-to-know-about-orforglipron
8.
Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613–626. doi:10.1016/S0140-6736(23)01200-X. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01200-X/fulltext
9.
Holst, J. J. (2019). From the incretin concept and the discovery of GLP-1 to today's diabetes therapy. Frontiers in Endocrinology, 10, 260. doi:10.3389/fendo.2019.00260. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6497767/
10.
Ismaiel, A., Scarlata, G. G. M., Boitos, I., et al. (2025). Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: A systematic review and network meta-analysis. International Journal of Obesity, 49(10), 1946–1957. doi:10.1038/s41366-025-01859-6. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12532569/
11.
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. doi:10.1056/NEJMoa2206038. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
12.
Kansakar, U., Jankauskas, S. S., Pande, S., et al. (2026). Orforglipron: A comprehensive review of an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes. International Journal of Molecular Sciences, 27(3), 1409. doi:10.3390/ijms27031409. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12898445/
13.
Ma, X., Liu, R., Pratt, E. J., et al. (2024). Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist. Diabetes Therapy, 15(4), 819–832. doi:10.1007/s13300-024-01554-1. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10951152/
14.
Mozaffarian, D., Agarwal, M., Aggarwal, M., et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. American Journal of Lifestyle Medicine. Advance online publication. doi:10.1177/15598276251344827. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12125019/
15.
Pandey, R. K., Jan, M., Mohammad, A., et al. (2025). Efficacy and safety of orforglipron in obese adults with or without diabetes: A systematic review and meta-analysis. Endocrinology, Diabetes & Metabolism, 8(6), e70134. doi:10.1002/edm2.70134. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12653021/
16.
Pechenov, S., Revell, J., Will, S., et al. (2021). Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease. Scientific Reports, 11, 22521. doi:10.1038/s41598-021-01750-0. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8602401/
17.
Rosenstock, J., Yabe, D., Cox, D., et al. (2026). Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): A multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. The Lancet, 407(10534), 1147–1160. doi:10.1016/S0140-6736(26)00202-3. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00202-3/fulltext
18.
Takrori, E., Peshin, S., Singal, S. (2025). Gastrointestinal adverse effects of anti-obesity medications in non-diabetic adults: A systematic review. Medicina, 61(11), 1987. doi:10.3390/medicina61111987. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12654588/
19.
U.S. Food and Drug Administration. (2026). FOUNDAYO (orforglipron) tablets, for oral use: Prescribing information. Retrieved from https://pi.lilly.com/us/foundayo-uspi.pdf
20.
VIVUS LLC. (n.d.). CONQUER study: Efficacy and safety. Qsymia [HCP website]. Retrieved from https://hcp.qsymia.com/efficacy-and-safety/study-conquer/
21.
Wadden, T. A., Foreyt, J. P., Foster, G. D., et al. (2011). Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity, 19(1), 110–120. doi:10.1038/oby.2010.147. Retrieved from https://pubmed.ncbi.nlm.nih.gov/20559296/
22.
Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine, 393(11), 1077–1087. doi:10.1056/NEJMoa2500969. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2500969
23.
Wharton, S., Aronne, L. J., Stefanski, A., et al. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine, 393(18), 1796–1806. doi:10.1056/NEJMoa2511774. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2511774
24.
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. doi:10.1056/NEJMoa2032183. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2032183